INDIVIDUAL TEST 355

Sulfatide Antibodies (IgM)

Indication

Suspicion of polyneuropathy

Sample material

Serum

• Minim. volume: 0,5 mL

CSF

• Minim. volume: 0,5 mL

Transport

Within Sweden

• room temperature

International

• cold

Method

ELISA

Reference interval

• < 10 negative

Result

Results are reported as negative, borderline, or positive with a ratio.

Interpretation

IgM antibodies against Sulfatide can occur in various types of neuropathy.

References

• Jacobs BC et al. IGOS Consortium. J Peripher Nerv Syst. 2017. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. PMID: 28406555
• Shang P et al. J Neurol. 2021. Axonal variants of Guillain-Barré syndrome: an update. PMID: 32140865
• Sheikh AB et al. J Neuroimmunol. 2021. Association of Guillain-Barre syndrome with COVID-19 infection: An updated systematic review. PMID: 33895700
• Van den Bergh PYK et al. J Peripher Nerv Syst. 2021. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. PMID: 34085743
• Wijdicks EF, Klein CJ. Mayo Clin Proc. 2017. Guillain-Barré Syndrome. PMID: 28259232
• Willison HJ et al. Lancet. 2016. Guillain-Barré syndrome. PMID: 26948435

Last updated: 2024-08-13